DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.

Abstract

Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of antidiabetic compounds, are effective in the treatment of hyperglycemia. Because atherosclerosis-related cardiovascular diseases are the major complications of diabetes, it is important to determine the effect of DPP-4 inhibitors on atherosclerosis. In this study, nondiabetic and diabetic… (More)
DOI: 10.1097/FJC.0b013e31821e5626

Topics

8 Figures and Tables

Cite this paper

@article{Ta2011DPP4I, title={DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice.}, author={Nga N Ta and Corinne A. Schuyler and Yanchun Li and Maria F. L. Lopes-Virella and Yan Huang}, journal={Journal of cardiovascular pharmacology}, year={2011}, volume={58 2}, pages={157-66} }